A Study of Four Dosing Regimens of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease. Protocol Addendum: Extension Study of Maintenance Therapy of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease.
PHASE2CompletedINTERVENTIONAL
Enrollment
267
Participants
Timeline
Start Date
September 30, 2005
Study Completion Date
February 28, 2007
Conditions
Chronic Kidney DiseaseAnemia
Interventions
DRUG
epoetin alfa
All Listed Sponsors
collaborator
Centocor Ortho Biotech Services, L.L.C.
INDUSTRY
lead
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
INDUSTRY
NCT00212875 - A Study of Four Dosing Regimens of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease. Protocol Addendum: Extension Study of Maintenance Therapy of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease. | Biotech Hunter | Biotech Hunter